secretori
pathway
cell
possess
elabor
set
endoproteolyt
enzym
carri
crucial
step
protein
precursor
matur
step
proteolyt
activ
cleavag
specif
pair
basic
residu
enzym
name
proprotein
convertas
pc
respons
gener
bioactiv
peptid
activ
sever
enzym
growth
factor
implic
mani
import
physiolog
event
pc
role
sever
patholog
includ
viral
infect
cancer
thu
promis
target
therapeut
applic
recent
structur
homologymodel
studi
demonstr
similar
expect
catalyt
site
seven
pc
make
develop
select
drug
target
individu
pc
frustrat
base
inform
review
latest
strategi
inhibit
pc
might
lead
develop
specif
compound
biolog
proprotein
convertas
pc
fundament
cell
infrastructur
proper
coordin
entir
mammalian
physiolog
endoproteolyt
action
inact
precursor
protein
secretori
pathway
pc
gener
essenti
bioactiv
peptid
includ
hormon
neuropeptid
eg
adrenocorticotrop
hormon
insulin
vital
role
homeostat
balanc
regul
life
function
also
activ
growth
factor
differenti
factor
protein
extracellular
matrix
plasma
enzym
receptor
viralcoat
protein
bacteri
toxin
pc
famili
enzym
encod
seven
gene
see
box
tabl
nomenclatur
archetyp
furin
studi
review
mammalian
pc
relat
yeast
kexin
bacteri
subtilisin
figur
present
structur
featur
pc
pc
ca
serin
proteas
identifi
origin
base
abil
cleav
precursor
protein
peptid
bond
ctermin
pair
basic
residu
kri
rri
howev
cleavagerecognit
motif
known
extend
ntermin
cleavag
site
often
includ
addit
arginin
residu
eg
rx
kr
ry
past
year
sever
import
patholog
link
pclike
activ
cellsecretori
pathway
cell
membran
aim
develop
inhibitor
target
individu
pc
everi
pc
implic
given
diseas
state
articl
review
involv
pc
variou
patholog
justifi
target
therapeut
applic
although
increas
evid
similar
variou
pc
rais
issu
whether
specif
compound
target
individu
pc
develop
five
major
approach
describ
articl
appear
make
possibl
increas
interest
pc
novel
target
drug
design
proteolyt
select
enzym
tissu
cellular
local
pattern
studi
extens
addit
welldefin
cellular
task
crucial
initi
progress
mani
import
diseas
promin
sever
viral
infect
cancer
exampl
furin
requir
activ
viral
coat
protein
glycoprotein
produc
virion
effect
receptor
bind
membran
fusion
infect
similar
pcmediat
process
requir
viral
spread
cytopath
also
occur
epsteinbarr
viru
gb
glycoprotein
hepat
b
viru
e
box
newli
adopt
pc
nomenclatur
antigen
sever
acut
respiratori
syndrom
coronaviru
spike
glycoprotein
role
make
drug
target
pc
potenti
antivir
agent
area
cancer
ongo
work
clarifi
pivot
role
pc
growth
regul
tumor
progress
activ
cancerpromot
factor
vascular
endotheli
growth
factor
c
vegfc
insulinlik
growth
factor
receptor
transform
growth
factor
b
tgfb
membran
type
matrix
metalloproteinas
addit
pcinhibit
studi
begin
provid
direct
evid
role
tumorigenesi
invas
evid
divers
role
pc
patholog
also
accumul
bacteri
pathogen
pseudomona
aeruginosa
exotoxin
protect
antigen
bacilliu
anthraci
tripartit
toxin
requir
furinmedi
cleavag
cytotox
reduc
block
pc
inhibitor
pc
role
neurodegen
age
maladi
alzheim
diseas
activ
prob
site
amyloidprecursorproteincleav
enzym
novel
bind
partner
bri
arthriti
process
tumor
necrosi
factor
aconvert
enzym
tace
coordin
interplay
uncov
recent
product
peptid
deriv
cocain
amphetamineregul
transcript
precursor
procart
believ
potenti
anorexia
thu
conclud
potenti
pc
inhibitor
novel
therapeut
agent
consider
warrant
analysi
date
pcorient
therapi
avail
achiev
goal
new
insight
need
molecular
determin
respons
proteolyt
activ
individu
pc
rational
develop
pc
inhibitor
strateg
mainstream
pc
inhibitor
develop
target
catalyt
site
base
fact
pc
highli
select
proteinas
cleav
uncommon
sequenc
motif
protein
eg
rxkr
howev
potent
inhibitor
known
date
target
catalyt
site
significantli
specif
singl
pc
compar
inhibitor
pc
show
mani
figur
pc
architectur
pc
highli
homolog
architectur
compos
ntermin
signal
peptid
respons
direct
protein
secretori
pathway
ii
prodomain
act
put
intramolecular
chaperon
facilit
transport
fold
regul
enzymat
activ
iii
catalyt
domain
contain
activ
site
respons
substratespecif
interact
cleavag
iv
p
domain
independ
fold
moieti
conform
barrellik
roll
essenti
structur
cohes
enzym
activ
regul
stabil
ca
phdepend
v
diverg
ctermin
domain
contain
membran
attach
sequenc
cysrich
region
intracellular
sort
signal
addit
furin
contain
two
function
group
intern
ionic
interact
ca
bind
site
one
beneath
activ
site
provid
stabil
aspart
h
histidin
serin
part
catalyt
triad
n
asparagin
locat
oxyanion
hole
stabil
nh
group
neg
charg
develop
peptid
bond
result
nucleophil
attack
catalyt
serin
least
two
isoform
b
identifi
encod
gene
high
potenc
specif
one
pc
figur
addit
pc
often
coexpress
within
cell
cell
express
cocktail
least
two
pc
thu
poorli
select
pc
inhibitor
affect
multipl
cellular
function
patholog
process
target
first
approach
develop
specif
pc
inhibitor
base
understand
molecular
determin
select
cleavag
pc
cleavag
site
numer
furin
substrat
align
assess
molecular
determin
howev
subsequ
cleavag
studi
show
mani
substrat
also
process
pc
emphas
recent
studi
transgen
inducibleknockout
mice
lack
furin
liver
known
substrat
furin
liver
eg
albumin
integrin
lipoproteinreceptorrel
protein
vitronectin
microglobulin
bikunin
either
process
partial
process
mice
indic
redund
pc
liver
data
also
underlin
potenti
undesir
effect
nonspecif
pc
inhibitor
inhibit
sever
pc
would
block
process
protein
desir
appli
therapeut
uniqu
specif
pc
inhibitor
potenti
advantag
use
combin
therapi
approach
simultan
block
two
pc
requir
current
develop
pc
inhibitor
base
newli
acquir
structur
model
inform
pc
ii
peptid
optim
combinatori
method
iii
engin
polypeptid
proteas
inhibitor
coevolv
pc
use
stabl
scaffold
graft
appropri
modif
specif
target
pc
iv
endogen
coevolutionari
inhibitor
v
small
nonpeptidyl
compound
deriv
approach
discuss
structur
molecular
model
approach
understand
molecular
basi
proprotein
process
pc
design
specif
inhibitor
benefit
recent
elucid
threedimension
conform
kinet
trap
furin
protein
data
bank
pdb
http
wwwrcsborgpdb
entri
molecul
yeast
homolog
kexin
pdb
entri
chain
crystal
structur
furin
provid
crucial
inform
spatial
arrang
two
domain
implic
pc
activ
catalyt
domain
contain
activ
site
respons
substratespecif
recognit
process
p
domain
respons
enzym
stabil
figur
crystal
structur
furin
coval
bound
complex
suicid
inhibitor
decanoylrvkrchloromethylketon
decrvkrcmk
led
identif
reactiv
amino
acid
make
subsit
pocket
structur
inform
permit
model
dock
analysi
led
extrapol
subsit
includ
subsit
pocket
figur
tabl
apart
subsit
pocket
activ
site
furin
contain
sever
protophil
carboxyl
carboxamid
explain
stringent
prefer
either
arginyl
lysyl
function
group
substrat
inhibitor
tabl
base
homolog
model
catalyt
domain
seven
pc
highli
homolog
level
ident
even
greater
residu
catalyticcleft
subsit
tabl
exampl
pc
subsit
interact
p
arginin
residu
substrat
compos
two
acid
aspart
acid
residu
tabl
three
residu
catalyt
triad
aspart
acid
histidin
serin
addit
nine
addit
amino
acid
provid
steric
environ
p
later
chain
ident
pc
illustr
comparison
furin
figur
subsit
ident
go
beyond
subsit
also
found
tabl
howev
differ
white
annot
indic
inhibitor
residu
black
annot
show
catalyt
triad
subsit
residu
c
represent
subsit
p
arginin
residu
furin
c
amino
acid
subsit
furin
close
proxim
within
shown
ballandstick
represent
wherea
p
arginin
render
ball
stick
mesh
surfac
comparison
demonstr
close
ident
subsit
except
furin
similar
analysi
subsit
pc
reveal
perfect
ident
furin
shown
catalyt
site
proteas
includ
pc
defin
subsit
posit
eg
correspond
residu
bind
substrat
inhibitor
p
p
p
thu
substrat
residu
posit
p
bind
subsit
pocket
proteas
subsit
compos
sever
amino
acid
substrat
inhibitor
residu
subsit
ctermin
side
cleavag
site
defin
prime
p
n
n
process
substrat
occur
p
p
peptidyl
bond
eg
p
n
p
p
p
yp
p
p
p
n
increas
away
catalyt
triad
subsit
pocket
beyond
observ
lower
expect
possibl
develop
short
peptid
inhibitor
pc
fourfiv
residu
specif
individu
pc
howev
differ
observ
subsit
indic
specif
shortpeptid
inhibitor
requir
least
six
residu
beyond
subsit
differ
might
exploit
design
specif
inhibitor
yet
differ
well
identifi
attempt
made
exampl
recent
studi
demonstr
exploit
catalyticsit
proxim
socal
adventiti
contact
lead
morespecif
inhibitor
map
proxim
site
also
aid
solutionstructur
studi
prodomain
subsequ
dock
analysi
pc
unlik
decrvkrcmk
map
four
subsit
posit
prodomaindock
analysi
demonstr
distinct
furin
pc
subsit
subsit
pocket
tabl
structur
studi
crystal
furin
pc
complex
differ
inhibitor
need
provid
better
understand
catalyt
site
pc
inhibitori
properti
smallpeptid
inhibitor
optim
vitro
use
posit
scan
synthet
peptid
combinatori
librari
psspcl
optim
sequenc
determin
screen
psspcl
embed
polypeptid
achiev
higher
specif
potenc
combinatori
librari
degener
mixtur
smallpeptid
inhibitor
use
success
compil
potent
sequenc
inhibit
furin
nonaarginin
identifi
previous
unknown
sequenc
llrvkr
potent
inhibit
latter
sequenc
identifi
novel
endogen
protein
precursor
prosaa
tissuedistribut
pattern
resembl
close
develop
nonaarginin
llrvkr
pc
inhibitor
demonstr
strength
psspcl
identifi
potent
inhibitori
peptid
sequenc
case
polyarginin
sequenc
peptid
rang
four
nine
residu
potent
inhibitor
furin
enantiomer
configur
potent
polyarginin
peptid
dnonaarginin
k
nm
interestingli
land
dpolyarginin
peptid
also
potent
inhibitor
et
al
unpublish
highlight
difficulti
achiev
substanti
specif
use
activ
site
exclus
therapeut
perspect
dpolyarginin
interest
lead
compound
cleav
pc
thu
stabl
dpeptid
therapeut
also
less
prone
proteolyt
activ
carboxypeptidas
dhexaarginin
block
activ
p
aeruginosa
exotoxin
dnonaarginin
partial
protect
macrophag
mice
anthrax
toxemia
lhexaarginin
effici
inhibitor
process
env
sequenc
vitro
ex
vivo
effect
suppress
infect
cell
macrophag
furin
two
princip
pc
express
hivhost
cell
best
candid
process
precursor
polyarginin
peptid
exhibit
undesir
interact
biolog
process
might
becom
key
compon
combin
therapi
target
furin
simultan
convers
introduc
polyarginin
peptid
sequenc
engin
polypeptid
might
achiev
greater
specif
retain
high
potenc
proteinbioengin
approach
astut
bioengin
proteas
inhibitor
coevolv
pc
also
led
develop
potent
pc
inhibitor
first
success
exampl
transform
potent
furin
inhibitor
insert
furinlik
recognit
sequenc
reactivesit
loop
bioengin
protein
name
antitrypsinportland
atpdx
inhibit
furin
without
alter
serpinlik
mechan
inhibit
review
potenti
therapeut
valu
atpdx
demonstr
abil
follow
exogen
applic
prevent
process
hiv
type
matur
ex
vivo
progb
precursor
human
cytomegaloviru
envelop
glycoprotein
bherpesvirida
recent
atpdx
test
cancerrel
applic
wherea
overexpress
furin
pc
associ
signific
increas
metastat
spread
potenti
tumorcel
prolifer
atpdx
decreas
invas
head
neck
squamouscel
carcinoma
vitro
inocul
tracheal
xenotranspl
express
atpdx
dna
vector
transfect
tumor
xenotranspl
astrocytoma
cell
also
suppress
effici
tumorigen
invas
although
atpdx
repres
strong
furin
case
target
pc
pathophysiolog
process
larg
size
protein
kda
limit
practic
applic
nonetheless
atpdx
might
use
effect
block
process
event
occur
outer
surfac
cell
membran
second
exampl
success
bioengin
approach
achiev
use
eglin
c
potent
inhibitor
elastas
cathepsin
g
degrad
subtilisin
initi
arginin
residu
insert
reactiv
site
loop
eglin
c
target
furin
kexin
random
strateg
eglin
c
residu
make
contact
pc
residu
outsid
catalyt
cleft
name
adventiti
contact
prove
extrem
effici
design
two
variant
eglin
c
target
either
furin
signific
specif
two
variant
c
k
pm
furin
nm
c
k
nm
furin
pm
demonstr
optim
flank
contact
vitro
molecular
evolut
provid
power
techniqu
gener
specif
inhibitor
pc
two
deriv
eglin
c
show
differ
outsid
near
activ
site
pc
favor
bind
affin
specif
inhibitor
eglin
c
variant
might
serv
biotechnolog
tool
dissect
function
furin
cell
membran
cocryst
process
lead
compound
design
potent
specif
smaller
therapeut
drug
endogen
approach
endogen
molecul
inhibit
pc
vivo
repres
major
lead
design
pharmacolog
inhibitor
pc
although
larg
polypeptid
core
inhibitori
domain
identifi
use
lead
compound
exampl
endogen
inhibitor
pc
prodomain
neuroendocrin
protein
prosaa
precursor
proteinas
inhibitor
review
contain
pcrecognit
sequenc
act
substrat
analog
real
substrat
fals
bait
pc
recent
inhibitori
effect
pc
two
new
candid
endogen
inhibitor
cystatinrel
epididym
spermatogen
cre
protein
serineproteas
inhibitor
describ
pc
prodomain
autoprocess
ci
cognat
pc
remain
bound
activ
site
ctermin
pcrecognit
sequenc
complex
reach
compart
zymogen
activ
thu
prodomain
dualfunct
molecul
first
substrat
first
inhibitor
encount
pc
cell
evalu
vitro
inhibitori
capac
seven
complet
prodomain
deriv
short
ctermin
dodecapeptid
demonstr
nanomolar
potenc
specif
howev
none
specif
inhibitor
uniqu
pc
lack
prodomain
specif
also
observ
inhibit
experi
cell
cultur
recent
overexpress
tran
chines
hamster
ovari
cho
cell
wildtyp
prodomain
select
key
residu
mutant
effici
inhibit
process
overexpress
substrat
provegfc
howev
matur
provegfc
also
decreas
significantli
express
prodomain
furin
cho
cell
date
indic
specif
inhibit
achiev
without
signific
structur
modif
prodomain
nevertheless
prodomain
multipl
interact
pc
outsid
catalyt
site
bioengin
might
result
specif
prodomain
cocryst
prodomainpc
complex
might
provid
inform
requir
map
interact
anoth
endogen
candid
cre
protein
diverg
function
cre
relat
famili
cystatin
famili
cysteineproteas
inhibitor
larger
cystatin
superfamili
inabl
cre
inhibit
cystein
proteas
presenc
two
access
pair
lysli
basicresidu
site
prompt
assumpt
cre
might
inhibit
assay
vitro
demonstr
cre
inhibit
furin
inhibit
occur
low
nanomolar
concentr
competit
indic
interact
catalyt
site
last
gene
drosophila
melanogast
encod
serpin
consensu
serpin
sequenc
hing
region
reactivesit
loop
rsl
indic
function
serpin
includ
natur
pcrecognit
sequenc
arg
arglysarg
rsl
vitro
inactiv
human
furin
k
pm
k
z
nm
slowbind
mechan
format
sdsstabl
acylenzym
complex
kinet
trap
typic
serpin
clade
exert
potent
inhibit
furin
indic
profound
lack
select
pc
gener
howev
remov
one
amino
acid
rsl
ala
gener
reduct
inhibit
potenc
ie
id
greater
effect
furin
chang
specif
indic
rsl
amend
modif
serpin
atpdx
chemic
approach
small
nonpeptidyl
compound
repres
poorli
explor
area
pc
inhibit
activ
pc
affect
metal
ion
first
inhibitori
chemic
compound
investig
ptolyl
terpyridin
ttp
chelat
metal
salt
zn
ttp
cl
cu
ttp
cl
bind
slowli
competit
irrevers
inhibitor
low
micromolar
inhibit
constant
ic
mm
possibl
chelatecoordin
interact
metal
catalyt
histidin
pc
although
free
chelat
alon
inhibitori
chelat
metal
salt
potent
solvat
metal
ion
thu
chelat
metalbas
inhibitor
gener
prodrug
serv
coordin
deliveri
drug
either
zn
cu
activ
site
pc
modif
adjust
chelat
might
lead
greater
inhibitori
affin
specif
pc
also
suggest
author
metallodrug
might
develop
widespectrum
pc
blocker
rapid
intervent
aggress
viral
infect
andor
bacteri
detoxif
improv
specif
inhibit
small
chemic
molecul
target
activ
site
might
prove
difficult
given
highli
conserv
amino
acid
pc
subsit
howev
small
chemic
molecul
possibl
obtain
librari
screen
might
lead
identif
compound
induc
alloster
conform
chang
select
affect
pc
activ
present
known
pc
alloster
site
ca
bind
site
appear
unlik
site
design
specif
pc
inhibitor
alloster
inhibit
pc
might
futur
avenu
research
mostli
unexplor
difficulti
map
alloster
site
identifi
ligand
caus
conform
chang
howev
screen
larg
librari
thiolcontain
compound
identifi
regulatori
site
away
activ
site
immobil
enzym
conform
form
revers
disulfid
bond
access
cystein
link
outer
site
activ
site
bind
specif
compound
block
interact
substrat
suggest
strategi
also
possibl
inhibit
pc
design
uniqu
specif
pc
inhibitor
repres
major
challeng
light
homolog
activ
site
famili
member
pc
inhibitor
potenti
becom
import
therapeut
agent
particularli
viral
diseas
possibl
cancer
addit
studi
design
specif
pc
inhibitor
identifi
molecular
determin
select
pc
ii
provid
new
pharmacolog
tool
probe
normal
pc
function
iii
defin
true
natur
compens
function
pc
challeng
identifi
small
signific
differ
away
core
activ
site
exploit
innov
classic
pharmacolog
drug
design
